Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
70 hedge funds and large institutions have $93.9M invested in Chinook Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 29 reducing their positions, and 27 closing their positions.
16% more call options, than puts
Call options by funds: $29K | Put options by funds: $25K
1% less capital invested
Capital invested by funds: $95.2M → $93.9M (-$1.27M)
22% less funds holding
Funds holding: 90 → 70 (-20)
52% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 29
74% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.69M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.55M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$907K |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$689K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$7.79M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$1.09M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$808K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$707K |
| 5 |
Renaissance Technologies
New York
|
-$698K |
KDNY Hedge Fund Activity: Q3 2020 in Review
70 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2020, worth a combined $93.9M — down 1.3% from $95.2M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of KDNY and 7 opened new positions — a net loss of 20 holders — while 29 trimmed existing stakes and 14 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $5.5M. The largest seller was Ikarian Capital, exiting entirely with an estimated $7.79M sold.
- 70 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2020, down from 90 in Q2 2020.
- Funds reported $93.9M of Chinook Therapeutics, Inc. Common Stock stock for Q3 2020, down 1.3% quarter-over-quarter.
- 7 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2020 and 27 closed out, a net change of -20 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q3 2020 was Point72 Asset Management, an estimated $5.5M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2020 was Ikarian Capital, an estimated $7.79M sold.
Based on aggregated 13F filings for Q3 2020.